Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 286 to 298 of 298 results for breast cancer

  1. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 19 April 2024.

    NICE guideline
    In consultation

  2. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370

    In development [GID-TA11513] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer TS ID 12010

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  6. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

    In development [GID-NG10419] Expected publication date: 31 March 2025

    NICE guideline
    In development

  8. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer

    In development [GID-DG10075] Expected publication date: 09 May 2024

    Diagnostics guidance
    In development